SCHEMBL5383485

SCHEMBL5383485

COC(Cc1cccc(OCCOc2ccc3c(c2)CCCC3)c1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARG P37231 13/20 0.62
PPARD Q03181 11/20 0.62
PPARA Q07869 9/20 0.57
POLB P06746 2/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
GFER P55789 1/20 0.48
PAX8 Q06710 1/20 0.48
KLF5 Q13887 1/20 0.48
MRGPRX4 Q96LA9 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
HSD17B10 Q99714 1/20 0.48
KDM4E B2RXH2 1/20 0.46
RXRA P19793 2/20 0.46
RXRB P28702 2/20 0.46
RXRG P48443 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14366610 1.00 PPARG (0.62) PPARGPPARDPPARAPOLBNPC1
SCHEMBL5374790 0.90 PPARG (0.73) PPARGPPARDPPARAPOLBNPC1
SCHEMBL5385708 0.87 PPARG (0.70) PPARGPPARDPPARAPOLBALOX15
SCHEMBL5379620 0.87 PPARG (0.70) PPARGPPARDPPARAPOLBALOX15
SCHEMBL5389329 0.86 PPARG (0.68) PPARGPPARDPPARAPOLBNPC1
SCHEMBL27871770 0.83 PPARG (0.57) PPARGPPARDPPARAL3MBTL1TSHR
SCHEMBL5389692 0.82 PPARG (0.56) PPARGPPARDPPARAMRGPRX4L3MBTL1
SCHEMBL14366608 0.82 PPARG (0.56) PPARGPPARDPPARAMRGPRX4L3MBTL1
SCHEMBL5379645 0.81 PPARG (0.72) PPARGPPARDPPARA
SCHEMBL14366609 0.80 PPARG (0.62) PPARGPPARDPPARAMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors ELI LILLY AND COMPANY 2005-01-27 US disclosed
EP-1392637-A2 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS ELI LILLY AND COMPANY (US) 2004-03-03 EP disclosed
WO-2002100813-A2 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS ELI LILLY AND COMPANY (US) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors NCOA4, PPARG, PPARA PPARG 2/4885PPARD 7/4885PPARA 3/4885
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors PPARG, NCOA4, PPARA PPARG 1/4885PPARD 4/4885PPARA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.